Evidence-Based Tools

Clinical Calculators

105 validated calculators and decision aids for cardiology and electrophysiology — organized by clinical domain with linked guidelines and references.

Section 1

General Clinical

Renal Function

Body Metrics & Dosing

Electrolytes & Metabolic

Hemodynamic Basics

Critical Care / Shock

Section 2

Prevention / Risk

PCE

ASCVD 10-Year Risk

ACC/AHA Pooled Cohort Equations — 10-year risk of a first atherosclerotic cardiovascular event. Primary tool guiding statin therapy decisions.

Open
New
FRS

Framingham Risk Score

Classic 10-year coronary heart disease risk model from the Framingham Heart Study — integrates age, cholesterol, BP, smoking, and diabetes.

Open
New
MESA

MESA Risk Score

MESA 10-year CHD risk score with optional coronary artery calcium integration — reclassifies intermediate-risk patients and guides statin initiation.

Open
New
LT

Lifetime ASCVD Risk

Lifetime cardiovascular risk estimation from the Framingham Offspring and Multi-Ethnic cohorts — motivates prevention in younger patients with low 10-year risk.

Open
New
CVA

Cardiovascular Age

Estimated cardiovascular age based on risk factor burden — compares patient's vascular age to chronological age to communicate prevention urgency.

Open
New
LDL

LDL Reduction / Statin Intensity

Expected LDL-C reduction for statin intensity classes — calculates target LDL and helps select appropriate statin dose per ACC/AHA guidelines.

Open
New
PREV

AHA PREVENT Calculator

2023 AHA PREVENT equations — 10- and 30-year CVD risk incorporating eGFR, HbA1c, and UACR. Replaces Pooled Cohort Equations as the guideline-recommended tool.

Open
New
SC2

SCORE2 / SCORE2-OP

ESC 2021 Systematic Coronary Risk Evaluation — 10-year fatal and non-fatal CVD risk calibrated by European region. SCORE2-OP extends to ages 70–89.

Open
New
Lp(a)

Lp(a)-Adjusted ASCVD Risk

Lipoprotein(a)-enhanced cardiovascular risk estimation — adjusts baseline ASCVD risk for elevated Lp(a) levels, informing emerging targeted therapies.

Open
New
S2OP

SCORE2-OP (Ages ≥70)

ESC 10-year cardiovascular risk calculator for older persons — adapts SCORE2 for ages ≥70 with competing-risk methodology accounting for non-CV mortality.

Open
Section 3

Acute Cardiology

Acute Coronary Syndromes

Pulmonary Embolism

Section 4

Heart Failure

Prognosis & Risk

SHFM

Seattle Heart Failure Model

1-, 2-, and 3-year mortality prediction in heart failure from the validated Levy 2006 model — integrates medications, labs, and hemodynamics.

Open
MAG

MAGGIC HF Mortality Score

3-year all-cause mortality risk in heart failure using the MAGGIC integer score — validated in 39,372 patients across 30 studies (Pocock 2013).

Open
HFH

HF Hospitalization Risk

1-year heart failure hospitalization risk in ambulatory HF patients — based on simplified CHARM risk factors including NYHA class and prior hospitalization.

Open
New
H₂FPE

H₂FPEF Score

Probability of HFpEF in patients with unexplained exertional dyspnea — 6-variable score from the Mayo Clinic, validated against PCWP measurements.

Open
New
HFA

HFA-PEFF Score

ESC HFA diagnostic algorithm for HFpEF — stepwise scoring using functional, morphological, and biomarker criteria with invasive confirmatory step.

Open
New
CPO

Cardiac Power Output

CO × MAP integration — the strongest hemodynamic predictor of in-hospital mortality in cardiogenic shock. Guides MCS device selection and escalation.

Open
New
RVSWI

RV Stroke Work Index

RV mechanical efficiency from right heart cath data — predicts RV failure risk after LVAD implant and guides perioperative management in advanced HF.

Open
New
IMCS

INTERMACS Profile

Interagency Registry for Mechanically Assisted Circulatory Support profiles 1–7 — classifies advanced HF severity to guide LVAD timing and transplant candidacy.

Open
New
MELD

MELD-XI Score

Modified MELD excluding INR — assesses hepato-renal dysfunction in advanced HF patients on anticoagulation. Predicts outcomes in LVAD and transplant candidates.

Open

Treatment Guidance

Section 5

Arrhythmias / Electrophysiology

Anticoagulation (AF)

CHA₂

CHA₂DS₂-VASc Score

Ischemic stroke risk stratification for atrial fibrillation — annual stroke/TE rate with anticoagulation recommendation per ACC/AHA 2023 guidelines.

Open
HAS

HAS-BLED Score

Major bleeding risk on anticoagulation — use alongside CHA₂DS₂-VASc for net clinical benefit assessment. Identifies modifiable bleeding risk factors.

Open
ORBIT

ORBIT Bleeding Risk Score

5-factor major bleeding risk in AF patients on OAC — validated alternative to HAS-BLED with simpler variables (O'Brien 2015, ORBIT-AF registry).

Open
SAMe

SAMe-TT₂R₂ Score

Predicts likelihood of achieving good anticoagulation control (high TTR) on warfarin in AF — guides DOAC vs. warfarin agent selection.

Open
New
ATRIA

ATRIA Bleeding Score

Anticoagulation and Risk Factors in Atrial Fibrillation — major hemorrhage risk score from the Kaiser Permanente ATRIA registry (Go 2003).

Open
New
GARF

GARFIELD-AF Risk Tool

Global GARFIELD-AF registry risk tool — simultaneously estimates 1-year stroke/SE and bleeding risk in newly diagnosed non-valvular AF patients.

Open
AF⚖

AF Net Clinical Benefit

Net clinical benefit of anticoagulation in AF — weighs CHA₂DS₂-VASc stroke risk against HAS-BLED bleeding risk using validated adjustment factors.

Open
New
EHRA

EHRA AF Symptom Score

European Heart Rhythm Association AF symptom classification (I–IV) — standardized grading of AF-related symptoms to guide rhythm vs. rate control strategy.

Open
New
CHAF

CHARGE-AF Risk Score

Cohorts for Heart and Aging Research in Genomic Epidemiology — predicts 5-year new-onset AF risk using clinical variables for screening and prevention decisions.

Open
New
DOAC

DOAC Renal Dosing Guide

Auto-calculated CrCl with drug-specific dose selection for all 4 DOACs — apixaban, rivaroxaban, dabigatran, edoxaban across AF, VTE, and prophylaxis indications.

Open
New
WAR

Warfarin Dose Adjustment

INR-based warfarin dose adjustment guide — covers subtherapeutic to supratherapeutic ranges, vitamin K reversal, 4-factor PCC dosing, and emergency protocols.

Open

QTc / Electrolytes

EP Arrhythmia Algorithms

WCT

Brugada Criteria for WCT

Modified Brugada 4-step algorithm — differentiates ventricular tachycardia from SVT with aberrant conduction using morphology and concordance criteria.

Open
aVR

Vereckei aVR Algorithm

4-step sequential algorithm using only lead aVR to differentiate wide complex tachycardia — VT vs SVT with aberrancy (Vereckei 2008).

Open
SVT

SVT Differential Diagnosis

Step-by-step narrow complex tachycardia algorithm — distinguishes sinus tach, AVNRT, AVRT, AT, flutter, and AF using RP interval and clinical features.

Open
WPW

WPW AP Localization

Simplified algorithm for accessory pathway localization in WPW syndrome — uses delta wave polarity and QRS transition across leads.

Open
AT

Atrial Tachycardia Localization

P-wave morphology algorithm to localize AT origin — crista terminalis, tricuspid annulus, pulmonary veins, coronary sinus, and other structures.

Open
iVT

Idiopathic VT Origin

Anatomic origin of idiopathic ventricular arrhythmias using QRS axis, transition, and morphology — RVOT, LVOT, fascicular, and other locations.

Open
VTO

VT Origin Predictor

Differentiate outflow tract (RVOT/LVOT), fascicular, and scar-mediated VT using QRS morphology, axis, precordial transition, and clinical history.

Open
VT

Ischemic VT Reentry Circuit

Pacing-based algorithm to identify VT reentry circuit location — entrainment maneuvers, concealed vs. overt fusion, and PPI-TCL interpretation.

Open
PVC

PVC Burden & CMP Risk

PVC-induced cardiomyopathy risk assessment using PVC burden, LVEF, QRS duration, and clinical risk factors. Guides monitoring and ablation decisions.

Open

Device & EP Risk

Section 7

Structural / Valve Disease

Surgical & Procedural Risk

Valve Severity Assessment

Section 8

Cardiac Imaging

Echocardiography

Hemodynamics (Cath Lab)

Disclaimer: All calculators and algorithms are validated clinical decision-support tools intended for use by licensed healthcare professionals. Results must be interpreted in the full clinical context of the individual patient. These tools support — but do not substitute — professional medical judgment. Full disclaimer →